Inclusion Criteria:  General:  ECOG performance status ≤1  • Disease Related:  Have a histologically or cytologically confirmed diagnosis of r/r B cell NHL or CLL or B-ALL as defined by WHO 2016 classification Subjects who received prior CD19-directed therapy must have disease that remains CD19+ Have measurable disease Have received ≥2 lines of therapy except subjects with MCL and WM, who must have received at least 1 prior line of therapy Have received a combination of an anti CD20 monoclonal antibody and cytotoxic chemotherapy for subjects with NHL  Received:  BTKi for subjects with MCL, CLL/SLL, WM, and other indications where a BTKi is approved Venetoclax for subjects with CLL/SLL Tyrosine kinase inhibitor for subjects with Philadelphia chromosome (Ph+) B-ALL Not responded or relapsed within 12 months of completion of their prior line of therapy, with the exception of a newly diagnosed Richter's transformation of CLL/SLL or other transformation of an indolent lymphoma, including from WM Adequate organ function White blood cell count of ≤20 × 109/L Platelet count ≥30,000/uL  Exclusion Criteria:  • Disease related:  Burkitt Lymphoma, primary CNS lymphoma, Richter's transformation to Hodgkin lymphoma Subjects with WM who underwent plasmapheresis <35 days prior to the first dose of NKX019 Subjects with NHL with any evidence of active CNS malignancy Subjects with B-ALL who have extramedullary disease (EMD) Subjects with any prior cellular therapy except subjects enrolling in selected LBCL expansion cohort who must have received prior CD19 directed CAR T therapy, recent HCT, or complications from HCT Recent use of any cancer-directed therapy within protocol specified window prior to the first dose of NKX019 Residual toxicities ≥Grade 2 due to prior therapy Other comorbid conditions and concomitant medications prohibited as per study protocol Pregnant or lactating female